Acer to Expand Diabetic Retinopathy Screening by Launching AI-assisted Diagnostic Solution to Local Hospitals and Clinics

Acer aims to help prevent blindness in diabetes patients by making eye screening more accessible for more people

Acer today announces the availability of VeriSee DR[1], an ophthalmic AI-assisted diagnostic solution for diabetic retinopathy (DR), to promote its early detection in Southeast Asia (SEA) countries. The program consists of three-month free use of VeriSee DR, as well as Acer antimicrobial[2] keyboard mouse sets to enable hospitals and clinics to conduct screening tests more efficiently. With the rise of diabetic patients, Acer hopes that by making screening more accessible, it can help detect high-risk cases and contribute to early diagnosis and treatment for DR patients.  

With a rapidly growing population of over 680 million people[3] in SEA, MedTech is booming in the region as governments and medical institutions look for smart healthcare solutions. In addition to the fast economic development and change of diet, many SEA countries have long been facing an increasing number of diabetic patients. According to recent estimates by the International Diabetes Federation (IDF), 90 million adults (aged 20-79) were living with diabetes in the SEA region in 2021, of which, 51% or 46 million are undiagnosed. The total adult diabetes population is estimated to increase to 113 million by 2030 and 152 million by 2045[4].  

As one of the world’s largest ICT brands, Acer leverages its technology expertise, combining with AI and rich clinical data to keep the company at the forefront of innovation in healthcare. VeriSee DR, a SaMD (software as a medical device), is the flagship AI product developed by Acer Group. The software uses AI to analyze images of diabetic patients’ retinas with ophthalmology-level of accuracy and give an immediate referral recommendation. It has already reached over a 50% adoption rate in medical centers in Taiwan.  

Through this initiative, VeriSee DR is now expanding its availability in Southeast Asia (SEA) countries. Acer plans to launch the DR screening program in the region in Q4 2022 ~ Q1 2023 and will also promote it to other SEA countries, including the Philippines, Vietnam, and India afterwards. The purpose of the program is to leverage AI-assisted screening software to ease the problem of limited healthcare resources – a shortage of doctors and to increase diagnostic efficiency for the local hospitals and clinics. Acer aims to help achieve a broader scale of DR screening, so diabetic patients can receive early treatment to avoid potential blindness.  

[1] VeriSee DR has a screening accuracy of 93%, which is comparable to ophthalmologists. It is an effective solution not only for physicians but also for ophthalmologists that can expedite the DR screening process, increase the volume of DR screenings, improve the accuracy and consistency of the DR results, and improve patient outcomes.    

[2] All antimicrobial solutions do not claim to protect users or provide any direct or implied health-benefit. 

[3] Worldometer   

[4] IDF Diabetes Atlas 10th Edition 2021